Foamix Expands International Patent Protection for its Emollient Foam Platform

Foamix Extends Collaboration with Galderma

Foamix Ltd. and VIB Sign Co-Development Agreement for Innovative Topical Therapy for Psoriasis

Promius Pharma, LLC Launches Scytera™ (Coal Tar) Foam 2% for Treatment of Psoriasis

Foamix is Finalist for International 2008 SCRIP Award

Ferndale and Foamix Execute License Agreement for Development of Non-Steroidal Foam for Atopic Dermatitis

Omnibus Survey:72% of Women Are Dissatisfied with Their Current Treament of Vaginal Infection

Foamix and Galderma to Develop Medicated Foam for Certain Skin Diseases

Foamix is a finalist for the Red Herring 100 Europe 2008 Award

BIRD invests $14m in 16 joint projects; English Hebrew

Foamix Announces New Foam Patent Approvals

Ferndale and Foamix Enter Development of an Innovative Foam for the Treatment of Atopic Dermatitis

Foamix Acquires Rights to Dual Chamber Aerosol Foam Technology

In-Pharma Technologist.com: Best Foam Forward

Foamix presents Innovative Intra-Vaginal Foam Delivery for Gynecology

Foamix Signs R&D Collaboration and License Agreement with Dr. Reddy’s for the Development and Commercialization of Psoriasis Foam

YNET: Collaboration with Warner Chilcott on gynecologic treatment (article in Hebrew)

Warner Chilcott and Foamix Collaborate on Gynecologic Foam Product

Foamix and Intendis Sign License Agreement for the Development of a Dermatological Foam

Globes: Foamix collaborates with Warner Chilcott on acne treatment

Warner Chilcott and Foamix Collaborate on Foam Product for the Treatment of Acne


 
November 2006

Emollient foam in topical drug delivery
Dov Tamarkin, PhD, Doron Friedman, PhD, Avner Shemer, MD, Foamix Ltd.

Abstract: Foams offer an innovative and more convenient means of topical drug delivery. The successful introduction of hydroalcoholic foams paved the way for the development of a new generation of foam products that provide skin barrier build-up and hydration. Such foams, designated as emollient foams consist of oil-in-water or water-in-oil emulsions with necessary excipients, such as non-ionic surfactants, gelling agents and foam adjuvants. Emollient foams can carry a broad variety of topical drugs, including water-soluble, oil-soluble and suspended active agents. This paper reviews emollient foam compositions and their physicochemical properties. It further accounts for the usability and functional advantages of emollient foam as a vehicle of topical drugs, including: i) improved usability, which affects treatment, compliance and, consequently, improves therapeutic results; ii) safety; iii) controllable drug delivery; iv) skin barrier build-up and hydration; and v) enhanced clinical efficacy.